Ankylosing Spondylitis Clinical Trial
Official title:
Effects of Pilates Training on Respiratory Muscle Strenght in Patients With Ankylosing Spondylitis
Background: Ankylosing Spondylitis (AS) is a chronic, inflammatory rheumatic disease that
effects primarily axial-spine. Reduction of flexibility and mobility is important factors
that can cause muscle weakness, impairment quality of life, reduction of exercise tolerance
and pulmonary capacity with the progression of AS. The purpose of this study is to
investigate the effects of pilates exercises on mobility, quality of life and respiratory
muscle strength in patients with AS.
Methods: Forty patients will be included who are aged between 18-55 years and got diagnosed
according to Modified New York criterias.Patients will be divided into two groups randomly.
Pilates training will be performed to the treatment group and conventional exercises will be
performed to the control group during 8 weeks. Respiratory muscle strength, quality of life,
spinal mobility, thorax expansion, respiratory functions, physical activity level, exercise
capasity and disease activity will be evaluated at first session and at the end of the 8th
week in this study.
Objective: Ankylosing Spondylitis (AS) is a chronic, inflammatory rheumatic disease that
effects primarily axial-spine. With progression of disease, flexibility of thorax and spine
will be get lost. It is reported that mobility, function, respiratory muscle strength and
endurance get worse in AS patients. Reduction of flexibility and mobility is important
factors that can cause muscle weakness, impairment quality of life, reduction of exercise
tolerance and pulmonary capacity with the progression of AS. To writer's knowledge, there has
been no study examining the effects of pilates exercises on mobility, function and
respiratory muscle strength in AS patients. The purpose of this study is to investigate the
effects of pilates exercises on mobility, function and respiratory muscle strength in
patients with AS.
Methods: Forty patients were included who are aged between 18-65 years and got diagnosed
according to Modified New York criterias. Patients who have incooperation, malignancy and
pregnancy will be excluded from the study. Patients will be divided into two groups randomly.
Pilates training will be performed to the treatment group and conventional exercises will be
performed to the control group during 8 weeks Respiratory muscle strength will be assessed by
maximal inspiratory and expiratory pressures. Thorax expansion will be measured from regions
of axillar, subcostal and epigastric by tape measure. To evaluate disease activity and spinal
mobility, we will use Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Bath
Ankylosing Spondylitis Metrology Index (BASMI), respectively. Quality of life will be
evaluated with Ankylosing Spondylitis Quality of Life Questionnaire (ASQoL). Exercise
capacity will be assessed by 6 minutes walk test. Pilates exercises will be performed 3 days
in a week for 8 weeks. Conventional exercise programme will be taugt to the control group and
requested to perform them at home. The assessments will be repeated in before and after
treatment.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT02685904 -
A Multicentre Study to Evaluate the Efficacy and Safety of ENIA11 in Patients With Ankylosing Spondylitis
|
Phase 3 | |
Completed |
NCT02186873 -
A Study of Golimumab in Participants With Active Ankylosing Spondylitis
|
Phase 3 | |
Completed |
NCT01668004 -
The Incidence of Extra-Articular Manifestations in Participants With Ankylosing Spondylitis Treated With Golimumab (MK-8259-012)
|
Phase 4 | |
Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
Completed |
NCT01934933 -
Etanercept and Celecoxib Alone/Combined Treatment in Effectiveness and Safety of Active Ankylosing Spondylitis
|
Phase 4 | |
Not yet recruiting |
NCT04875299 -
Optimal Adalimumab Plasma Concentrations in Ankylosing Spondylitis Patients
|
||
Completed |
NCT02758782 -
NSAIDs Added to Anti-TNF Therapy Versus Anti-TNF Therapy Alone on Progression of Structural Damage in Ankylosing Spondylitis
|
Phase 4 | |
Completed |
NCT02763111 -
Clinical Trial to Evaluate Efficacy and Safety of Multiple Subcutaneous Injections of Various Doses of BCD-085 in Patients With Active Ankylosing Spondylitis
|
Phase 2 | |
Active, not recruiting |
NCT02687620 -
Does Immunogenicity Have an Influence on the Efficacy of Anti-TNF Therapy in Patients With AS: An Inception Cohort Study
|
||
Completed |
NCT02154425 -
A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers
|
Phase 1 | |
Completed |
NCT01750528 -
Prevalence and Progression of Periodontitis in Ankylosing Spondylitis
|
N/A | |
Completed |
NCT01463189 -
Web-based Support to Manage Arthritis Pain
|
Phase 2 | |
Completed |
NCT01091675 -
Assessment of the Response to Etoricoxib in Patients With Ankylosing Spondylitis and Inadequate Response to ≥2 NSAIDs
|
Phase 3 | |
Completed |
NCT00844805 -
Infliximab for Treatment of Axial Spondyloarthritis (P05336 AM1)
|
Phase 3 | |
Recruiting |
NCT00747578 -
Health-Related Quality of Life and Disease-Related Costs: Comparison Between Ankylosing Spondylitis, Rheumatoid Arthritis and Systemic Lupus Erythematosus in Taiwan
|
N/A | |
Completed |
NCT01083693 -
Quality of Life Outcomes of HUMIRA in Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS) After Unsustainable Response to Biologicals and Disease Modifying Antirheumatic Drugs
|
N/A | |
Completed |
NCT00715091 -
Effects of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) on RAdiographic Damage in Ankylosing Spondylitis
|
Phase 4 | |
Not yet recruiting |
NCT00517101 -
Presence of IBD Specific Antibodies (ASCA, ALCA, ACCA, AMCA) in the Sera of Patients With Spondyloarthropathy
|
N/A | |
Completed |
NCT00367211 -
Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PN 200 or Naproxen in Subjects Who Are at Risk for Developing NSAID-Associated Ulcers.
|
Phase 3 | |
Completed |
NCT00133315 -
TNFalfa Blocking Treatment of Spondylarthropathies
|
Phase 4 |